Business Context and Reporting Period
This Form 6-K filing by Compugen Ltd. covers the month of October 2004, specifically dated October 19, 2004. Compugen is a genomics-based drug and diagnostic discovery company headquartered in Tel-Aviv, Israel. The company utilizes mathematical, computer science, and physics methods to create predictive models for biological phenomena, advancing therapeutic and diagnostic product discovery. Its operations include an in-house pipeline of therapeutic protein candidates, out-licensed discoveries, and subsidiaries Keddem Bioscience (small-molecule drug discovery) and Evogene (agricultural biotechnology).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report serves solely to disclose a corporate event and does not contain financial statements or quantitative performance data.
Material Changes
No material financial changes versus a prior comparable period are reported in this filing. The document focuses exclusively on an upcoming corporate presentation.
Guidance, Outlook, and Management Commentary
Management announced that Martin Gerstel, Chairman of the Board, is scheduled to present at the Rodman & Renshaw Techvest 6th Annual Healthcare Conference. The presentation is set for 10:45 AM Eastern Time on Thursday, October 28, 2004, at The Waldorf Astoria in New York City. A live webcast and a 90-day replay will be available on the company's investor website. The filing reiterates the company's strategic focus on integrating computational methods with biology and chemistry to enhance drug discovery probabilities.
Investor Verification Checklist
- Verify the date and time of the upcoming presentation by Chairman Martin Gerstel at the Rodman & Renshaw conference.
- Confirm the availability of the live webcast and replay on the official Compugen investor relations website.
- Review the company's current pipeline status and partnership agreements with major pharmaceutical firms (e.g., Abbott, Novartis, Pfizer) as described in the "About Compugen" section.
- Note that this filing contains no financial data; refer to the most recent Form 20-F for audited financial statements.